Anlotinib after disease progression for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether continuing anlotinib after the cancer has progressed can help people with advanced lung cancer. It looks at real-world treatment records to see if this approach keeps the cancer stable longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced lung cancer (non-small cell or small cell) that has spread to other parts of the body.
- Your cancer must not have certain treatable gene changes (driver gene negative).
- You must have taken anlotinib and continued it for at least 4 months after your cancer grew.
- You must have had a scan within 90 days before restarting treatment and at least two scans afterward.
- You cannot have used other targeted anti-angiogenic drugs (like bevacizumab or many others) before or after anlotinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with extensive-stage small cell lung cancer that has stopped responding to at least two previous treatments. The goal is to see if this combination can help control the cancer when other options have failed.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.